AstraZeneca’s Tozorakimab meets primary endpoint in Phase III COPD trial
AstraZeneca (NASDAQ:AZN) today announced positive high-level results from its pivotal Phase III MIRANDA trial, evaluating tozorakimab as a maintenance treatment for patients with chronic obstructive pulmonary disease (COPD).











